Key Drivers
- Strong liquidity
- Pre‑revenue status
- High cash burn
AIAI Summary
SYRE has shifted from a long‑shot biotech to a catalyst‑driven, late‑stage story—its ~$757–$783M runway materially de‑risks near‑term financing and makes multiple Phase‑2 readouts in 2026 the clear value drivers, so investors should take a selective, event‑weighted position size (or hedged exposure) ahead of SKYLINE/SKYWAY while preparing for binary downside if one or more readouts fail.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Pre‑revenue status
- •High cash burn
SYRE has a very strong, low‑leverage balance sheet and ample cash/investments but is pre‑revenue with heavy R&D‑driven losses and negative free cash flow that make its high market valuation risky.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Near support
- •Failed retest
SYRE is in a mild downtrend over the last month, failing to break the $44.0–$44.2 resistance and trading near the $39.90–$41.60 support, with a sharp pullback from $44.07 to $41.25 signaling short-term selling risk.
Sharp pullback from $44.07 on 2026-03-16 to $41.25 on 2026-03-20 (~−6.4%)
Sentiment & News
Key News Insights:
- •Institutional accumulation
- •Clinical acceleration
- •Personnel investment
Spyre Therapeutics saw institutional accumulation, active investor engagement, strategic hiring grants and positive clinical momentum (strong buy, longer SPY001 half-life, accelerated RA recruitment) through March 2026.
These signals increase near-term upside likelihood by improving funding/visibility and suggest a higher probability of a Q3 2026 RA data-driven catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings